Cantor Fitzgerald set a $29.00 target price on Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) in a research report sent to investors on Thursday. The brokerage currently has a buy rating on the stock.
A number of other equities research analysts have also issued reports on SBPH. Dawson James reaffirmed a buy rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. ValuEngine raised Spring Bank Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, August 17th. Chardan Capital reissued a buy rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. Finally, B. Riley assumed coverage on Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They set a buy rating and a $30.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $27.25.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) traded down $0.25 during mid-day trading on Thursday, reaching $15.64. The company had a trading volume of 27,560 shares, compared to its average volume of 41,729. Spring Bank Pharmaceuticals has a 12-month low of $6.31 and a 12-month high of $18.93.
WARNING: This piece was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/19/cantor-fitzgerald-analysts-give-spring-bank-pharmaceuticals-inc-sbph-a-29-00-price-target.html.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.